SETD2-deficient RCC cells display heightened dependence on replication-stress response pathways; preclinical work shows synergy between SETD2 loss and ATR inhibition, with augmented cGAS–STING activation and antitumor immunity. This evidence concerns the gene STING1 and renal cell carcinoma.